SEARCH

SEARCH BY CITATION

References

  • Seeff LB. Diagnosis, therapy, and prognosis of viral hepatitis. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease. Philadelphia, PA: WB Saunders; 1982: 911977.
  • Chalmers TC, Reynolds WE, Eckhardt RD, Cigarroa JG, Reifenstein WE, Smith CW, et al. Treatment of acute infectious hepatitis in the armed forces: advantages of ad lib bed rest and early reconditioning. JAMA 1955; 159: 14311434.
  • Huber TE, Wiley AT. Cortisone in the treatment of infectious hepatitis. Ann Intern Med 1955; 42: 10111025.
  • Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 10091022.
  • Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66: 924931.
  • Ferenci P. Historical treatment of chronic hepatitis B and C. Gut 1993; 34(suppl): S69-S73.
  • Greenberg HB, Pollard RB, Litwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295: 517522.
  • Feinstone SM, Kapikian AZ, Puecell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975; 292: 767770.
  • Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383398.
  • Pappas SC, Hoofnagle JH, Young, N, Straus SE, Jones EA. Treatment of chronic non-A, non-B hepatitis with acyclovir: a pilot study. J Med Virol 1985; 15: 19.
  • Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986; 315: 15751578.
  • Di Bisceglie A, Martin P, Kassianedes C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo controlled trial. N Engl J Med 1908; 321: 15061510.
  • Davis GL, Balart L, Schiff E, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Intervention Therapy Group. N Engl J Med 1989; 321: 15011506.
  • Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled trial. J Hepatol 1996; 25: 591598.
  • McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 14851492.
  • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352: 14261432.
  • Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazal-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821829.
  • Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, et al. A sustained virological response is durable in patients with chronic hepatitis C treated with peginterferon alpha-2a and ribavirin. Gastroenterology 2010; 139: 15931601.
  • Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C: a cure and so much more. Clin Infect Dis 2011; 52: 889900.
  • Reddy RK, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon apha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433438.
  • Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 16661673.
  • Lindsay KL, Trepo C, Heinges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001. 34: 395403.
  • Pawlotsky JM, Roudot-Thoraval F, Bastie A, Darthuy F, Remire J, Metreau JM, et al. Factors effecting treatment responses to interferon-alpha in chronic hepatitis C. J Infect Dis 1996; 174: 17.
  • Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26(suppl 1): 122S-127S.
  • Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 13431350.
  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al.; for PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • Buti M, Sanchez Avila F, Lurie Y, Staglis C, Valdes A, Martell M, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35: 930936.
  • Lindahl K, Stahle L, Bruchfeld A, Schvarez R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275279.
  • Bert T, von Wagner M, Nasser S, Sarazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 10861097.
  • Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46: 16881694.
  • Jensen DM, Morgan RT, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954960.
  • Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425433.
  • Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola RM, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124134.
  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marions G, Goncales Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645652.
  • Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100: 24532462.
    Direct Link:
  • Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci 2007; 52: 732736.
  • Cornberg M, Hadem J, Hermann E, Schuppert F, Schmidt HH, Reiser M, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 2006; 44: 291301.
  • Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 24292441.
  • Fujisawa T, Inui A, Ohkawa T, Komastu H, Miyakawa Y, Onoue M. Response to interferon therapy in children with chronic hepatitis C. J Pediatr 1995; 127: 660662.
  • Christensson B, Wiebe T, Akesson A, Widell A. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000; 30: 585586.
  • Gonzalez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005; 42: 10101018.
  • Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002; 36: 12801284.
  • Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 10131018.
  • Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected patients. Aids 2004; 351: 451459.
  • Torriani FJ, Rodriquez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected persons. N Engl J Med 2004; 351: 438450.
  • Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 28392848.
  • Soriano V, Bravo R, Garcia-Samaniego J, Castilla J, Gonzalez J, Castro A, et al. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. Hepatitis/HIV Spanish Study Group. Aids 1997; 11: 400401.
  • Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 15731580.
  • Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, et al. The treatment for chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 768774.
  • Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; 73(suppl 109): S1-S99.
  • Carriero D, Fabrizi F, Uriel AJ, Paark J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008; 31: 295302.
  • Fagiuoli S, Cooper DK, Zuhdi N. Hepatitis C status of heart transplant recipients. Clin Transplant 1998; 12: 510.
  • Doucette KE, Weinkauf J, Sumner S, Ens K, Lien D. Treatment of hepatitis C in potential lung transplant candidates. Transplantation 2007; 83: 16521655.
  • Sugawaara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation: Transplantation 2004; 78: 13081311.
  • Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27: 14031407.
  • Hebling B, Jochum W, Stamenic I, Knopfli M, Cerny A, Borovicka J, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006; 13: 762769.
  • Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350355.
  • Iaccobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patient with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206221.
  • Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470477.
  • Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 17021708.
  • Rosen HR, Weston SJ, Im K, Yang H, Burton JR Jr, Erlich H; for Virahep C Study Group. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of anti-viral therapy. Hepatology 2007; 46: 350358.
  • Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis 2010; 30: 333347.
  • Lin C, Kwoong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3/4A serine protease. Infect Disord Drug Targets 2006; 6: 316.
  • Reesink HW, Zeusem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology 2006; 131: 9971002.
  • Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Martin W, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 17671777.
  • McHutchinson JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 18271838.
  • Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al.; for PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 18391850.
  • McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al.; for PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 12921303.
  • Kwo PY, Lawitz EJ, McCane J, Schiff ER, Vierling JM, Pound D, et al.; for SPRINT-1 Investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705716.
  • Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; for SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 11951206.
  • Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.; for HCV RESPOND-2 Investigators. N Engl J Med 2011; 364: 12071217.
  • Sherman KE, Flamm SL, Afdahl NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 10141024.
  • Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; for American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 14331444.